Unibest

Pharmaceutical Intermediates

Full official intermediate catalog + key intermediates with CEP / DMF / GMP / cold-chain qualifications and capacity details · each quotable via RFQ

Enquire by CASView API Products →

2026 Key Intermediate Campaigns →

4 target drugs · 7 key intermediates
Lenacapavir3 CAS

Antiviral (HIV-1)

Marketed (US · EU · both treatment and prevention indications)
Orforglipron2 CAS

Metabolic (obesity / type 2 diabetes)

Phase 3 positive · NDA submitted to FDA (under review)
Inavolisib1 CAS

Oncology (breast cancer)

Marketed (FDA-approved first-line combination in Oct 2024)
Osilodrostat1 CAS

Endocrine (Cushing's syndrome)

Marketed (US 2020 · EU 2020 · China 2024)

Featured ProductsProven track record · documents on request

Enter hub →
Others469General Chemicals282Acids116Alcohols32Ketones17Esters43Alkanes17Phenols10
Dealt

Orforglipron intermediates

Sample orders (500 g each) + 0.5 kg repeat order

2 deals completed · latest 2026-09-21

Documents in progress

Dealt

PINACOLONE

Dual-use item (trade control category)

2 deals completed · latest 2026-01-19

Documents in progress

Dealt

4-(3-Bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline

CAS 543737-10-6

1 deal completed · latest 2026-07-08

Documents in progress

Dealt

L-Tyrosine disodium salt, dihydrate

177 deals completed · latest 2026-09-10

Open for inquiry →

Dealt

Choline chloride

CAS 67-48-1

143 deals completed · latest 2026-09-21

Open for inquiry →

Dealt

D-Glucose Anhydrous

137 deals completed · latest 2026-09-22

Open for inquiry →

Patent-cliff opportunities · recommended intermediates

Ranked by opportunity score · source: patent-cliff radarOpen opportunity profile →

semaglutide

68
API0–18 monthsSouth Asia

Intermediate list in preparation — inquiries welcome

Key opportunity markets: India / Bangladesh / Pakistan

olaparib

66
API18–36 monthsNorth America
· 2-Fluoro-5-formylbenzonitrile218301-22-5· 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]benzonitrile763114-25-6· 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin -1-yl)Methyl)benzoic acid763114-26-7

Key opportunity markets: United States / Canada / Mexico

apixaban

62
Generic FDF0–18 monthsEurope
· 3-Chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one536760-29-9· 3-Morpholino-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one503615-03-0· 1-(4-Aminophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one1267610-26-3

Key opportunity markets: United Kingdom / Germany / Italy

sacubitril/valsartan

62
Generic FDF0–18 monthsEast Asia and Oceania

Intermediate list in preparation — inquiries welcome

Key opportunity markets: China / Japan / South Korea

tirzepatide

61
API3–7 yearsEast Asia and Oceania
· AEEA-HCl134979-01-4· AEEA-AEEA1143516-05-5· Boc-AEEA-AEEA1069067-08-8

Key opportunity markets: China / Japan / South Korea

sacubitril/valsartan

61
Generic FDF0–18 monthsNorth America

Intermediate list in preparation — inquiries welcome

Key opportunity markets: United States / Canada / Mexico

Region is inferred coarsely from your browser IP (region-level only, IP not stored). Opportunity scores are internal radar ratings, not a commitment.

By Therapeutic Area of Target Drug

Click a class to filter both sections below; classes follow the target API's primary indication
Metabolic / Endocrine62

Diabetes, obesity, dyslipidemia, NASH and other metabolic diseases

Cardiovascular / Renal58

Hypertension, heart failure, anticoagulation, chronic kidney disease

Oncology / Hematology193

Solid tumours, haematologic malignancies, myeloproliferative diseases

Anti-infectives17

Antiviral, antibacterial, antifungal, HIV / hepatitis

Immunology / Inflammation36

RA, psoriasis, atopic dermatitis, IBD

CNS / Psychiatry46

Epilepsy, pain, depression & anxiety, neurodegeneration

Gastroenterology / Hepatology28

Acid-related, GI motility, diarrhoea, liver disease

Respiratory11

COPD, asthma and other airway diseases

Urology / Women's Health35

Menopausal symptoms, urological conditions

Ophthalmology2

Glaucoma, ocular surface disease

Dermatology0

Skin infection, dermatologic inflammation

Anesthesia / Analgesia0

Local anaesthesia, postoperative analgesia

Allergy4

Allergic rhinitis, urticaria

Animal Health14

Companion-animal ectoparasiticides

Unclassified506

Qualified Key IntermediatesCEP / DMF / GMP / Cold-chain / Capacity / Price-band details

17 items
Product / CASPurity / Impurity profile (redacted)Synthesis route (redacted)CapacityQualificationsPackaging / Cold-chainMOQ / Price bandAction
Lenacapavir INT-1 | N-Boc chiral amine ester
CAS 1620056-47-4 · Antivirals
Target drug: lenacapavir
Highly confidential
≥99.0%
Single impurity ≤0.10%, total impurities ≤0.50% (redacted)
chiral reduction + Boc protection (redacted summary)1,200 kg/yr
US DMF
5 kg / 25 kg drum (aluminium foil bag liner)
1 kg
US$ 2,600-3,800 / kg
Unibest Nantong cGMP Site
Lenacapavir INT-2 | 4- chloro -7- boronate indazole
CAS 2189684-53-3 · Antivirals
Target drug: lenacapavir
Highly confidential
≥98.5%
Related-substance profile available in the CDA data room
indazole construction + Miyaura borylation (redacted summary)900 kg/yr
US DMF
1 kg / 5 kg aluminium bottle
Cold chain
0.5 kg
US$ 4,200-6,000 / kg
Unibest Nantong cGMP Site
Lenacapavir INT-3 | cyclopropane-fused cyclopentane pyrazole acetic acid
CAS 1620056-83-8 · Antivirals
Target drug: lenacapavir
Highly confidential
≥99.0%
Chiral purity ≥99.5% ee (redacted)
bicyclic construction + trifluoromethylation (redacted summary)700 kg/yr
US DMF
1 kg aluminium bottle
Cold chain
0.5 kg
US$ 5,800-8,200 / kg
Unibest Nantong cGMP Site
Lenacapavir INT-4 | 3- methyl -3-(methanesulfonyl)-1- butyne
CAS 2109226-54-0 · Antivirals
Target drug: lenacapavir
Visible after CDA
≥98.0%
Single impurity ≤0.20% (redacted)
alkynylation + sulfone introduction (redacted summary)2,400 kg/yr
25 kg drum
5 kg
US$ 780-1,150 / kg
Unibest Taizhou GMP-like Site
Lenacapavir (GS-6207) API
CAS 2189684-44-2 · Antivirals
Target drug: lenacapavir
Highly confidential
≥99.5%
Single impurity ≤0.10%, total impurities ≤0.30% (redacted)
convergent coupling + salt formation (redacted summary)300 kg/yr
US DMFEU GMP
100 g / 1 kg aluminium bottle (closed system)
Cold chain
100 g
🔒 Available after CDA
Unibest Nantong cGMP Site
Doravirine INT-1 | 3- chloro -5-[(pyridyl) oxy] benzonitrile
CAS 1155846-86-8 · Antivirals
Target drug: doravirine
Visible after CDA
≥99.0%
Single impurity ≤0.15% (redacted)
aromatic nucleophilic substitution ether formation (redacted summary)3,600 kg/yr
US DMFEU GMP
25 kg drum
10 kg
US$ 420-620 / kg
Qualified Partner — East China API Works
Doravirine INT-2 | 3- chloro -5- iodophenol
CAS 861347-86-6 · Antivirals
Target drug: doravirine
≥99.0%
Single impurity ≤0.15% (redacted)
selective iodination (redacted summary)5,200 kg/yr
25 kg drum
25 kg
US$ 210-320 / kg
Qualified Partner — East China API Works
Entecavir INT-1 | purine nucleoside intermediate
CAS 142217-80-9 · Antivirals
Target drug: entecavir
≥99.0%
Single impurity ≤0.10% (redacted)
glycosylation + protecting-group strategy (redacted summary)1,800 kg/yr
CEPUS DMFEU GMP
5 kg / 25 kg drum
5 kg
US$ 1,150-1,700 / kg
Qualified Partner — East China API Works
Orforglipron INT-1 | 5- bromo -4- fluoro -1- methyl indazole
CAS 1784678-61-0 · GLP-1 (metabolic)
Target drug: orforglipron
Highly confidential
≥99.0%
Single impurity ≤0.10% (redacted)
indazole ring construction + N-methylation (redacted summary)2,000 kg/yr
US DMF
5 kg / 25 kg drum
5 kg
US$ 1,850-2,600 / kg
Unibest Nantong cGMP Site
Orforglipron INT-2 | (S)-4- methyl -1,3,2- dioxathiolane -2,2- dioxide
CAS 174953-30-1 · GLP-1 (metabolic)
Target drug: orforglipron
Highly confidential
≥99.0%
Chiral purity ≥99.5% ee (redacted)
chiral diol cyclic sulfate formation (redacted summary)1,500 kg/yr
5 kg drum
5 kg
US$ 980-1,450 / kg
Unibest Nantong cGMP Site
Orforglipron INT-3 | (4- fluoro -3,5- dimethyl phenyl) hydrazine hydrochloride
CAS 2212021-40-2 · GLP-1 (metabolic)
Target drug: orforglipron
Visible after CDA
≥98.5%
Single impurity ≤0.20% (redacted)
diazotisation–reduction (redacted summary)3,000 kg/yr
25 kg drum
10 kg
US$ 560-820 / kg
Unibest Taizhou GMP-like Site
Orforglipron INT-4 | (S)-3- aminobutyronitrile hydrochloride
CAS 1073666-54-2 · GLP-1 (metabolic)
Target drug: orforglipron
Visible after CDA
≥99.0%
Chiral purity ≥99.5% ee (redacted)
asymmetric synthesis + salt formation (redacted summary)2,200 kg/yr
25 kg drum
10 kg
US$ 640-950 / kg
Unibest Taizhou GMP-like Site
Belzutifan INT-1 | (R)-3- fluoro -5-[(indanonyl) oxy] benzonitrile
CAS 2738675-96-0 · Anti-cancer
Target drug: belzutifan
Highly confidential
≥99.0%
Chiral purity ≥99.5% ee (redacted)
chiral reduction + ether formation (redacted summary)800 kg/yr
US DMF
1 kg / 5 kg aluminium bottle
1 kg
US$ 3,400-4,900 / kg
Unibest Taizhou GMP-like Site
Belzutifan INT-2 | 3-[(indanonyl) oxy]-5- fluoro benzonitrile
CAS 1672665-55-2 · Anti-cancer
Target drug: belzutifan
Highly confidential
≥99.0%
Single impurity ≤0.10% (redacted)
ether formation + sulfone oxidation (redacted summary)1,100 kg/yr
5 kg drum
2 kg
US$ 2,100-3,100 / kg
Unibest Taizhou GMP-like Site
2'-dG(iBu) phosphoramidite monomer
CAS 68892-42-2 · Nucleic Acids
Target drug: oligonucleotide
≥99.0%
Single impurity ≤0.10% (redacted)
nucleoside protection + phosphitylation (redacted summary)400 kg/yr
US DMFEU GMP
100 g / 1 kg aluminium bottle
Cold chain
100 g
US$ 1,600-2,400 / 100g
Unibest Nantong cGMP Site
2'-dA(Bz) phosphoramidite monomer
CAS 4546-72-9 · Nucleic Acids
Target drug: oligonucleotide
≥99.0%
Single impurity ≤0.10% (redacted)
nucleoside protection + phosphitylation (redacted summary)400 kg/yr
US DMFEU GMP
100 g / 1 kg aluminium bottle
Cold chain
100 g
US$ 1,480-2,200 / 100g
Unibest Nantong cGMP Site
2'-dC(Bz) phosphoramidite monomer
CAS 4836-13-9 · Nucleic Acids
Target drug: oligonucleotide
≥99.0%
Single impurity ≤0.10% (redacted)
nucleoside protection + phosphitylation (redacted summary)350 kg/yr
US DMFEU GMP
100 g / 1 kg aluminium bottle
Cold chain
100 g
US$ 1,520-2,280 / 100g
Unibest Nantong cGMP Site

Official Intermediate Full CatalogWith CAS numbers · Aggregated by target drug

Total 995 intermediates · covering 255 target drugs
Page 1 / 17
123…17Next ›
Intermediate nameCAS No.Target drugAction
(2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoic acid1012341-50-2(LCZ696)
(R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoic acid1012341-48-8(LCZ696)
AHU-377 (heMicalciuM salt)1369773-39-6(LCZ696)
1H-BenziMidazole, 6-(2-chloro-5-fluoro-4-pyriMidinyl)-4-fluoro-2-Methyl-1-(1-Methylethyl)-1231930-42-9Abemaciclib
2,4-Dichloro-5-fluoropyrimidine2927-71-1Abemaciclib
5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-amine1180132-17-5Abemaciclib
6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole1231930-33-8Abemaciclib
3-Oxocyclobutane-1-carboxylicacid23761-23-1Abrocitinib
benzyl ((1s,3s)-3-(methylamino)cyclobutyl)carbamate1353501-22-0Abrocitinib
Benzyl 3-oxocyclobutylcarbamate130369-36-7Abrocitinib
Carbamic acid, N-[cis-3-(methylamino)cyclobutyl]-, phenylmethyl ester, hydrochloride (1:1)2204290-99-1Abrocitinib
(S)-Benzyl 2-(8-amino-1-bromoimidazo[1,5 -a]pyrazin-3- yl)pyrrolidine-1-carboxylate1420478-88-1Acalabrutinib
[4-[(Pyridin-2-yl)carbamoyl]phenyl]boronic acid850568-25-1Acalabrutinib
2-Butynoic Acid590-93-2Acalabrutinib
2-Butynoyl Chloride39753-54-3Acalabrutinib
3-Chloro-2-pyrazinemethanamine hydrochloride939412-86-9Acalabrutinib
4-[8-Amino-3-(2S)-2-pyrrolidinylimidazo[1,5 -a]pyrazin-1-yl]-N-2- pyridinylbenzamide1420478-90-5Acalabrutinib
(S)-2-(Piperazin-2-yl)acetonitrile dihydrochloride2158301-19-8Adagrasib
(S)-7-(8-chloronaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol2408250-15-5Adagrasib
1-Bromo-8-chloronaphthalene20816-79-9Adagrasib
2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile2206737-06-4Adagrasib
2-FLUOROACRYLIC ACID430-99-9Adagrasib
7-(8-chloronaphthalen-1-yl)-2-(isopropylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol2898538-61-7Adagrasib
7-(8-chloronaphthalen-1-yl)-2-mercapto-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol2898538-57-1Adagrasib
7-Benzyl-2,4-dichloro-5,6,7,8-tetrahydropyrido[3,4-d]pyriMidine1059735-34-0Adagrasib
8-chloronaphthalen-1-amine59107-51-6Adagrasib
Ethyl N-benzyl-3-oxo-4-piperidine-carboxylate hydrochloride52763-21-0Adagrasib
methyl 1-(8-chloronaphthalen-1-yl)-3-oxopiperidine-4-carboxylate2898538-56-0Adagrasib
sodium 2-fluoroacrylate74893-46-2Adagrasib
tert-butyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate916420-27-4Adagrasib
N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-aMine162012-67-1Afatinib
1-[3-Chloro-5-trifluoromethylphenyl]-2,2,2-trifluoroethanone1125812-58-9Afoxolaner
4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-1-naphthoic acid1308362-48-2Afoxolaner
4-acetyl-1-naphthoic acid131986-05-5Afoxolaner
2-(4-ethyl-3-iodophenyl)-2-Methylpropanoic acid1256584-73-2Alectinib Hydrochloride
4-(piperidin-4-yl)morpholine53617-35-9Alectinib Hydrochloride
tert-butyl 4-(4-ethyl-3-iodophenyl)-4-methyl-3-oxopentanoate1256584-74-3Alectinib Hydrochloride
tert-butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan -2-yl)-1Hindole-3-carboxylate1256584-75-4Alectinib Hydrochloride
tert-butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate1256584-75-4Alectinib Hydrochloride
[[(1a,3b,5E,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3-diyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethylsilane]112670-85-6Alfacalcidol
BRN 471587565445-14-9Alfacalcidol
(R)-2-[[6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-y]methyl]-4-fluorobenzonitrile865759-25-7Alogliptin/ Trelagliptin
(R)-3-(Boc-Amino)piperidine309956-78-3Alogliptin/ Trelagliptin
(R)-3-aminopiperidine dihydrochloride334618-23-4Alogliptin/ Trelagliptin
2-[(6-Chloro-3,4-dihydro-3-methy1-2,4-dioxo-1(2H)-pyrimidinyl)methyl]benzonitrile865758-96-9Alogliptin/ Trelagliptin
2-Cyano-5-fluorobenzyl bromide421552-12-7Alogliptin/ Trelagliptin
2-Cyanobenzyl bromide22115-41-9Alogliptin/ Trelagliptin
6-Chloro-3-methyluracil4318-56-3Alogliptin/ Trelagliptin
6-Chlorouracil4270-27-3Alogliptin/ Trelagliptin
1-(Diphenylmethyl)-3-hydroxyazetidine18621-17-5Anidulafungin
4-(4'-Pentoxy-4-biphenylyl)benzoic acid158938-08-0Anidulafungin
4''-(Pentyloxy)-[1,1':4',1''-terphenyl]-4-carboxylic acid158938-08-0Anidulafungin/ Rezafungin
1-amino-N-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]Cyclobutanecarboxamide1950587-17-3Apalutamide
5-Amino-3-(trifluoromethyl)picolinonitrile573762-62-6Apalutamide
N-Boc-1-aminocyclobutanecarboxylic acid120728-10-1Apalutamide
1-(4-Aminophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one1267610-26-3Apixaban
1-(4-Methoxyphenyl)-7-0xo-6-[4-(2-0xopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acidethyl ester503614-91-3Apixaban
3-Chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one536760-29-9Apixaban
3-Morpholino-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one503615-03-0Apixaban
3-Morpholino-1-[4-(2-oxopiperidin-1-yl)phenyl]-5,6-dihydropyridin.2(1H)-one545445-44-1Apixaban
Page 1 / 17Next ›